<DOC>
	<DOCNO>NCT00551460</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , gemtuzumab , block cancer growth different way . Some find cancer cell help kill carry cancer-killing substance . Others interfere ability cancer cell grow spread . Gemtuzumab may also stop growth promyelocytic leukemia block blood flow cancer . Giving gemtuzumab together combination chemotherapy may effective treat promyelocytic leukemia . PURPOSE : This phase II trial study well give gemtuzumab together combination chemotherapy work treat patient previously untreated promyelocytic leukemia .</brief_summary>
	<brief_title>S0535 , Gemtuzumab Combination Chemotherapy Treating Patients With Previously Untreated Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To assess event-free survival death first six week patient previously untreated , high-risk acute promyelocytic leukemia treat combined regimen tretinoin , arsenic trioxide , gemtuzumab ozogamicin . - To estimate frequency severity toxicity regimen group patient . - To investigate molecular response rate utilizing regimen high-risk patient . OUTLINE : - Induction chemotherapy : Patients receive oral tretinoin twice daily begin day 1 CR ( 90 day ) , gemtuzumab ozogamicin IV 2 hour day 1 , arsenic trioxide IV 2 hour 5 day week begin day 10 CR ( 60 day ) absence disease progression unacceptable toxicity . Patients achieve A1 bone marrow , B1 peripheral blood , C1 extramedullary disease status proceed consolidation therapy maintain B1 peripheral blood status ≥ 7 day . - Consolidation therapy : Beginning 2-8 week documentation complete response ( CR ) , patient receive consolidation therapy . - Consolidation course 1 2 : Patients receive arsenic trioxide IV 2 hour 5 day week 5 week . Treatment repeat every 7 week 2 course . Patients remain A1 bone marrow , B1 peripheral blood , C1 extramedullary disease status continue consolidation course 3 4 . - Consolidation course 3 4 : Within 4 week complete consolidation course 2 , patient receive oral tretinoin twice daily day 1-7 daunomycin IV bolus 1 hour day 1-3 . Within 2-8 week recovery B1 peripheral blood status , patient receive consolidation course 4 course 3 . Patients remain B1 peripheral blood C1 extramedullary disease status continue consolidation course 5 6 . - Consolidation course 5 6 : Beginning 2-8 week recovery B1 peripheral blood status , patient receive gemtuzumab IV 2 hour day 1 . Between 2-8 week recovery B1 peripheral blood status , patient receive consolidation course 6 course 5 . Patients remain A1 bone marrow , B1 peripheral blood , C1 extramedullary disease status proceed maintenance therapy . - Maintenance therapy : Beginning 2-8 week recovery blood count , patient receive oral tretinoin twice daily day 1-7 every week 1 year , oral mercaptopurine daily 1 year , oral methotrexate weekly 1 year . Patients undergo bone marrow aspirate biopsy periodically study . Samples analyze cytogenetics fluorescence situ hybridization ( FISH ) PML-RARα polymerase chain reaction ( PCR ) . After completion study treatment , patient evaluate 3 , 6 , 9 , 12 , 18 , 24 , 36 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically confirm acute promyelocytic leukemia ( APL ) base bone marrow examination APLRARαnegative RTPCR eligible Highrisk disease , define WBC &gt; 100,000/mm^3 Bone marrow specimen must make available cytogenetic study PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prolong QTc &gt; 0.47 sec No malignancy within past 5 year , except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I stage II cancer patient currently complete remission PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy acute leukemia At least 3 day since prior tretinoin ( ATRA ) allow Prior hydroxyurea , corticosteroid , leukapheresis control high cell count allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>